Avi Biopharma, Inc.
Records under this name other than the patents Avi Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,030,291 | Antisense antiviral compounds and methods for treating a filovirus infection Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,030,292 | Antisense antiviral compounds and methods for treating a filovirus infection Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,067,571 | Antibacterial antisense oligonucleotide and method Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,168,604 | Antisense antiviral compounds and methods for treating a filovirus infection Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,582,615 | Antisense Antiviral Compound and Method for Treating Arenavirus Infection Formerly held In force · High confidence | In force | High confidence | |
| US 8,053,420 | Peptide conjugated, inosine-substituted antisense oligomer compound and method Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,790,694 | Antisense antibacterial method and compound Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,536,147 | Antibacterial antisense oligonucleotide and method Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,759,307 | Oligonucleotide compound and method for treating nidovirus infections Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,161,948 | Peptide Oligonucleotide Conjugates Formerly held In force · Medium confidence | In force | Medium confidence |